Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC)
- PMID: 29924959
- PMCID: PMC6087551
- DOI: 10.17305/bjbms.2018.2378
Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC)
Abstract
Extensive research is being conducted to identify novel diagnostic, predictive and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC), as only a few markers have been routinely used so far with limited success. Our aim was to assess the expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), E-cadherin, and γ-catenin in PDAC in relation to clinicopathological parameters and patient survival. We also investigated if there is a correlation of NEDD9 expression with E-cadherin or γ-catenin. The protein expression was determined by immunohistochemistry in 61 PDAC and 61 samples of normal pancreatic tissue. The log rank test and Kaplan-Meier survival curve were used for survival analysis. E-cadherin and γ-catenin expressions were reduced in PDAC, and completely retained in normal pancreatic tissue. Expression of NEDD9 was significantly increased in PDAC (strong expression in 78.7% of cases and moderate in 21.3%) and reduced in normal pancreatic tissue (strong positivity in 45.9% of cases, moderate in 31.1%, and weak in 23%). There was a positive correlation between reduced E-cadherin and γ-catenin expression in PDAC (p = 0.015). The loss or reduced expression of E-cadherin had a negative impact on patient survival (p = 0.020). A negative correlation between E-cadherin expression and tumor grade was also observed (p = 0.011). Decreased E-cadherin expression was more common in male patients with PDAC (81.3% vs. 60% for females, p = 0.005). γ-catenin and NEDD9 expressions were not statistically correlated with tumor stage and grade, gender, nor with patient survival. Our results support the role of NEDD9, E-cadherin and γ-catenin proteins in PDAC, but further research should clarify in detail their mechanism of action in pancreatic cancer.
Figures
Similar articles
-
Expression of the E-cadherin-catenin complex in patients with pancreatic ductal adenocarcinoma.Folia Histochem Cytobiol. 2010 Jan 1;48(1):128-33. doi: 10.2478/v10042-008-0089-1. Folia Histochem Cytobiol. 2010. PMID: 20529828
-
Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.Pathol Oncol Res. 2013 Apr;19(2):281-6. doi: 10.1007/s12253-012-9580-2. Epub 2012 Oct 20. Pathol Oncol Res. 2013. PMID: 23086683
-
Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.J Clin Pathol. 2017 Jul;70(7):619-624. doi: 10.1136/jclinpath-2016-204028. Epub 2016 Dec 15. J Clin Pathol. 2017. PMID: 27980052
-
Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.Clin Chim Acta. 2019 Jan;488:226-234. doi: 10.1016/j.cca.2018.11.023. Epub 2018 Nov 16. Clin Chim Acta. 2019. PMID: 30452897 Review.
-
Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28. Clin Cancer Res. 2011. PMID: 21444679 Review.
Cited by
-
Unraveling dynamically encoded latent transcriptomic patterns in pancreatic cancer cells by topic modeling.Cell Genom. 2023 Aug 23;3(9):100388. doi: 10.1016/j.xgen.2023.100388. eCollection 2023 Sep 13. Cell Genom. 2023. PMID: 37719139 Free PMC article.
-
Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway.Front Oncol. 2021 Sep 6;11:754146. doi: 10.3389/fonc.2021.754146. eCollection 2021. Front Oncol. 2021. PMID: 34552882 Free PMC article.
-
MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9.Aging (Albany NY). 2021 Jul 27;13(14):18924-18945. doi: 10.18632/aging.203344. Epub 2021 Jul 27. Aging (Albany NY). 2021. PMID: 34314382 Free PMC article.
-
Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis.Front Oncol. 2021 Apr 12;11:627116. doi: 10.3389/fonc.2021.627116. eCollection 2021. Front Oncol. 2021. PMID: 33912451 Free PMC article.
-
Expression of NEDD9 and connexin-43 in neoplastic and stromal cells of gastric adenocarcinoma.Bosn J Basic Med Sci. 2021 Oct 1;21(5):542-548. doi: 10.17305/bjbms.2020.5379. Bosn J Basic Med Sci. 2021. PMID: 33485292 Free PMC article.
References
-
- Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol. 2009;6(12):699–708. https://doi.org/10.1038/nrgastro.2009.177. - PubMed
-
- Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, et al. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol. 2013;34(2):895–9. https://doi.org/10.1007/s13277-012-0624-8. - PubMed
-
- Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16(7):3327–37. https://doi.org/10.1128/MCB.16.7.3327. - PMC - PubMed
-
- Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125(7):1269–81. https://doi.org/10.1016/j.cell.2006.06.008. - PubMed
-
- Ahn J, Sanz-Moreno V, Marshall CJ. Metastasis gene NEDD9 acts through integrin b3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci. 2012;125(7):1814–26. https://doi.org/10.1242/jcs.101444. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
